A detailed history of Two Sigma Investments, LP transactions in Anavex Life Sciences Corp. stock. As of the latest transaction made, Two Sigma Investments, LP holds 830,624 shares of AVXL stock, worth $7.17 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares
830,624
Previous 1,012,883 17.99%
Holding current value
$7.17 Million
Previous $4.27 Million 10.36%
% of portfolio
0.01%
Previous 0.01%

Shares

11 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$4.11 - $7.04 $749,084 - $1.28 Million
-182,259 Reduced 17.99%
830,624 $4.72 Million
Q2 2024

Aug 14, 2024

BUY
$3.39 - $5.02 $1.62 Million - $2.4 Million
477,336 Added 89.13%
1,012,883 $4.27 Million
Q1 2024

May 15, 2024

BUY
$4.55 - $6.75 $2.23 Million - $3.3 Million
489,046 Added 1051.69%
535,547 $2.73 Million
Q4 2023

Feb 14, 2024

SELL
$5.04 - $9.95 $415,875 - $821,024
-82,515 Reduced 63.96%
46,501 $432,000
Q3 2023

Nov 14, 2023

BUY
$6.55 - $9.37 $83,289 - $119,148
12,716 Added 10.93%
129,016 $845,000
Q2 2023

Aug 14, 2023

SELL
$7.66 - $9.5 $1.1 Million - $1.37 Million
-143,730 Reduced 55.27%
116,300 $945,000
Q1 2023

May 15, 2023

BUY
$8.32 - $11.75 $958,946 - $1.35 Million
115,258 Added 79.61%
260,030 $2.23 Million
Q4 2022

Feb 14, 2023

BUY
$7.65 - $14.43 $15,192 - $28,657
1,986 Added 1.39%
144,772 $1.34 Million
Q3 2022

Nov 14, 2022

BUY
$8.9 - $12.86 $562,622 - $812,957
63,216 Added 79.45%
142,786 $1.47 Million
Q2 2022

Aug 15, 2022

SELL
$7.31 - $12.84 $272,392 - $478,456
-37,263 Reduced 31.89%
79,570 $796,000
Q1 2022

May 16, 2022

BUY
$9.74 - $17.69 $1.14 Million - $2.07 Million
116,833 New
116,833 $1.44 Million

Others Institutions Holding AVXL

About ANAVEX LIFE SCIENCES CORP.


  • Ticker AVXL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 77,942,800
  • Market Cap $673M
  • Description
  • Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of drug candidates for the treatment of central nervous system (CNS) diseases. Its lead drug candidate is ANAVEX 2-73, which is in Phase III clinical trial for the treatment of Alzheimer's disease; Phase III clinical trial to treat pediatric patien...
More about AVXL
Track This Portfolio

Track Two Sigma Investments, LP Portfolio

Follow Two Sigma Investments, LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Two Sigma Investments, LP, based on Form 13F filings with the SEC.

News

Stay updated on Two Sigma Investments, LP with notifications on news.